Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis
We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocar...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 1997-05, Vol.75 (9), p.1247-1255 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1255 |
---|---|
container_issue | 9 |
container_start_page | 1247 |
container_title | British journal of cancer |
container_volume | 75 |
creator | Bjørge, L Junnikkala, S Kristoffersen, EK Hakulinen, J Matre, R Meri, S |
description | We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement. |
doi_str_mv | 10.1038/bjc.1997.213 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2228228</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9155042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-cdca62b55e69c8a146d0dd40be1cab8ea07c0e02026124d7f7af000c7dae978f3</originalsourceid><addsrcrecordid>eNp1kM9LwzAYhoMoc05vXoUcPNqZZG3TXgQZ_oKBKHoOX5OvW0bbjKQb7L83Y2PoQQiE8D55v4-HkGvOxpxNivtqqce8LOVY8MkJGfJsIhJeCHlKhowxmbBSsHNyEcIyPktWyAEZlDzLWCqG5OMTgw09dBqpq6nbgLfQ0R499E6D17ZzLVCNTUPDaoHeWRNo76h27arBFrs-adFY6NHQZhu7LslZDU3Aq8M9It_PT1_T12T2_vI2fZwlOpW8T7TRkIsqyzAvdQE8zQ0zJmUVcg1VgcCkZsgEEzkXqZG1hDrur6UBLGVRT0bkYd-7WldxAx038dColbct-K1yYNXfpLMLNXcbJYQo4okFd_sC7V0IHuvjX87UzqyKZtXOrIpmI37ze94RPqiM-e0hh6ChqX10asMRE3mWlbFnRJI9FmLSzdGrpVv7Lpr6byzd8x30a4_HvgjtmB3yA74FnjE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Bjørge, L ; Junnikkala, S ; Kristoffersen, EK ; Hakulinen, J ; Matre, R ; Meri, S</creator><creatorcontrib>Bjørge, L ; Junnikkala, S ; Kristoffersen, EK ; Hakulinen, J ; Matre, R ; Meri, S</creatorcontrib><description>We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1997.213</identifier><identifier>PMID: 9155042</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antibodies, Monoclonal - pharmacology ; Antibody-Dependent Cell Cytotoxicity - immunology ; Antigens, CD - biosynthesis ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; CD55 Antigens - biosynthesis ; CD59 Antigens - biosynthesis ; Complement Activation ; Complement Inactivator Proteins - biosynthesis ; Complement System Proteins - physiology ; Cytotoxicity, Immunologic - drug effects ; Drug Resistance ; Epidemiology ; experimental-oncology ; Female ; Female genital diseases ; Flow Cytometry ; Fluorescent Antibody Technique, Indirect ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Membrane Cofactor Protein ; Membrane Glycoproteins - biosynthesis ; Molecular Medicine ; Oncology ; Ovarian Neoplasms - immunology ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Spheroids, Cellular - immunology ; Spheroids, Cellular - metabolism ; Spheroids, Cellular - pathology ; Teratocarcinoma - immunology ; Teratocarcinoma - metabolism ; Teratocarcinoma - pathology ; Tumor Cells, Cultured ; Tumors</subject><ispartof>British journal of cancer, 1997-05, Vol.75 (9), p.1247-1255</ispartof><rights>Cancer Research Campaign 1997</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-cdca62b55e69c8a146d0dd40be1cab8ea07c0e02026124d7f7af000c7dae978f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228228/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228228/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2725,27923,27924,41487,42556,51318,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2655921$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9155042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bjørge, L</creatorcontrib><creatorcontrib>Junnikkala, S</creatorcontrib><creatorcontrib>Kristoffersen, EK</creatorcontrib><creatorcontrib>Hakulinen, J</creatorcontrib><creatorcontrib>Matre, R</creatorcontrib><creatorcontrib>Meri, S</creatorcontrib><title>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibody-Dependent Cell Cytotoxicity - immunology</subject><subject>Antigens, CD - biosynthesis</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>CD55 Antigens - biosynthesis</subject><subject>CD59 Antigens - biosynthesis</subject><subject>Complement Activation</subject><subject>Complement Inactivator Proteins - biosynthesis</subject><subject>Complement System Proteins - physiology</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>experimental-oncology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Flow Cytometry</subject><subject>Fluorescent Antibody Technique, Indirect</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Membrane Cofactor Protein</subject><subject>Membrane Glycoproteins - biosynthesis</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Spheroids, Cellular - immunology</subject><subject>Spheroids, Cellular - metabolism</subject><subject>Spheroids, Cellular - pathology</subject><subject>Teratocarcinoma - immunology</subject><subject>Teratocarcinoma - metabolism</subject><subject>Teratocarcinoma - pathology</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9LwzAYhoMoc05vXoUcPNqZZG3TXgQZ_oKBKHoOX5OvW0bbjKQb7L83Y2PoQQiE8D55v4-HkGvOxpxNivtqqce8LOVY8MkJGfJsIhJeCHlKhowxmbBSsHNyEcIyPktWyAEZlDzLWCqG5OMTgw09dBqpq6nbgLfQ0R499E6D17ZzLVCNTUPDaoHeWRNo76h27arBFrs-adFY6NHQZhu7LslZDU3Aq8M9It_PT1_T12T2_vI2fZwlOpW8T7TRkIsqyzAvdQE8zQ0zJmUVcg1VgcCkZsgEEzkXqZG1hDrur6UBLGVRT0bkYd-7WldxAx038dColbct-K1yYNXfpLMLNXcbJYQo4okFd_sC7V0IHuvjX87UzqyKZtXOrIpmI37ze94RPqiM-e0hh6ChqX10asMRE3mWlbFnRJI9FmLSzdGrpVv7Lpr6byzd8x30a4_HvgjtmB3yA74FnjE</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>Bjørge, L</creator><creator>Junnikkala, S</creator><creator>Kristoffersen, EK</creator><creator>Hakulinen, J</creator><creator>Matre, R</creator><creator>Meri, S</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19970501</creationdate><title>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</title><author>Bjørge, L ; Junnikkala, S ; Kristoffersen, EK ; Hakulinen, J ; Matre, R ; Meri, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-cdca62b55e69c8a146d0dd40be1cab8ea07c0e02026124d7f7af000c7dae978f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibody-Dependent Cell Cytotoxicity - immunology</topic><topic>Antigens, CD - biosynthesis</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>CD55 Antigens - biosynthesis</topic><topic>CD59 Antigens - biosynthesis</topic><topic>Complement Activation</topic><topic>Complement Inactivator Proteins - biosynthesis</topic><topic>Complement System Proteins - physiology</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>experimental-oncology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Flow Cytometry</topic><topic>Fluorescent Antibody Technique, Indirect</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Membrane Cofactor Protein</topic><topic>Membrane Glycoproteins - biosynthesis</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Spheroids, Cellular - immunology</topic><topic>Spheroids, Cellular - metabolism</topic><topic>Spheroids, Cellular - pathology</topic><topic>Teratocarcinoma - immunology</topic><topic>Teratocarcinoma - metabolism</topic><topic>Teratocarcinoma - pathology</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bjørge, L</creatorcontrib><creatorcontrib>Junnikkala, S</creatorcontrib><creatorcontrib>Kristoffersen, EK</creatorcontrib><creatorcontrib>Hakulinen, J</creatorcontrib><creatorcontrib>Matre, R</creatorcontrib><creatorcontrib>Meri, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bjørge, L</au><au>Junnikkala, S</au><au>Kristoffersen, EK</au><au>Hakulinen, J</au><au>Matre, R</au><au>Meri, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>75</volume><issue>9</issue><spage>1247</spage><epage>1255</epage><pages>1247-1255</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>9155042</pmid><doi>10.1038/bjc.1997.213</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 1997-05, Vol.75 (9), p.1247-1255 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2228228 |
source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
subjects | Antibodies, Monoclonal - pharmacology Antibody-Dependent Cell Cytotoxicity - immunology Antigens, CD - biosynthesis Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research CD55 Antigens - biosynthesis CD59 Antigens - biosynthesis Complement Activation Complement Inactivator Proteins - biosynthesis Complement System Proteins - physiology Cytotoxicity, Immunologic - drug effects Drug Resistance Epidemiology experimental-oncology Female Female genital diseases Flow Cytometry Fluorescent Antibody Technique, Indirect Gynecology. Andrology. Obstetrics Humans Medical sciences Membrane Cofactor Protein Membrane Glycoproteins - biosynthesis Molecular Medicine Oncology Ovarian Neoplasms - immunology Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Spheroids, Cellular - immunology Spheroids, Cellular - metabolism Spheroids, Cellular - pathology Teratocarcinoma - immunology Teratocarcinoma - metabolism Teratocarcinoma - pathology Tumor Cells, Cultured Tumors |
title | Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A42%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resistance%20of%20ovarian%20teratocarcinoma%20cell%20spheroids%20to%20complement-mediated%20lysis&rft.jtitle=British%20journal%20of%20cancer&rft.au=Bj%C3%B8rge,%20L&rft.date=1997-05-01&rft.volume=75&rft.issue=9&rft.spage=1247&rft.epage=1255&rft.pages=1247-1255&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1997.213&rft_dat=%3Cpubmed_cross%3E9155042%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9155042&rfr_iscdi=true |